Synthesis and Evaluation of Amino Acid-Based Radiotracer 99mTc-N4-AMT for Breast Cancer Imaging by Kong, Fan-Lin et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 276907, 7 pages
doi:10.1155/2011/276907
Research Article
SynthesisandEvaluationofAminoAcid-Based Radiotracer
99mTc-N4-AMT forBreastCancerImaging
Fan-LinKong,Mohammad S.Ali,YinhanZhang, Chang-SokOh, Dong-FangYu,
Mithu Chanda,and DavidJ.Yang
Department of Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, TX 77030, USA
Correspondence should be addressed to Fan-Lin Kong, fanlin.kong@mdanderson.org
Received 30 December 2010; Accepted 14 February 2011
Academic Editor: Lie-Hang Shen
Copyright © 2011 Fan-Lin Kong et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose.T h i ss t u d yw a st od e v e l o pa ne ﬃcient synthesis of 99mTc-O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-α-methyl
tyrosine(99mTc-N4-AMT) andevaluate its potential incancer imaging.Methods.N4-AMT was synthesized by reacting N4-oxalate
and 3-bromopropyl AMT (N-BOC, ethyl ester). In vitro cellular uptake kinetics of 99mTc-N4-AMT was assessed in rat mammary
tumorcells.Tissuedistributionoftheradiotracerwasdetermined innormalratsat0.5–4h,whileplanarimagingwasperformedin
mammarytumor-bearing rats at30–120min. Results.The totalsynthesis yield ofN4-AMT was 14%.Cellularuptake of 99mTc-N4-
AMT wassigniﬁcantlyhigher than thatof 99mTc-N4. Planarimagingrevealed that 99mTc-N4-AMT rendered greater tumor/muscle
ratios than 99mTc-N4. Conclusions. N4-AMT could be synthesized with a considerably high yield. Our in vitro and in vivo data
suggest that 99mTc-N4-AMT, a novel amino acid-based radiotracer, eﬃciently enters breast cancer cells, eﬀectively distinguishes
mammary tumors from normaltissues, and thus holds the promise for breast cancer imaging.
1.Introduction
18F-ﬂuoro-deoxy-glucose(FDG),an 18F-labeledglucoseana-
log, is the most common radiotracer for positron emission
tomography (PET) in cancer diagnosis [1]. However, FDG-
PET has several limitations in practice, for example, FDG
cannot distinguish tumor tissues from inﬂammatory or
normal brain tissues. Therefore, 18F-labeled amino acid-
based radiotracers have been reported as an alternative,
which is based on the fact that tumor cells take up and
c o n s u m em o r ea m i n oa c i d st om a i ntain their sustained fast
growth. Among those radiotracers, 18F-labeled alpha-methyl
tyrosine (AMT) has shown high tumor uptake and great
ability to diﬀerentiate tumor tissue from inﬂammatory sites
in brain tumors and squamous cell carcinoma [2]. 18F-AMT
enters the tumor cells via L-type amino acid transporters
(LAT), which is the only system that can transport large
neutral amino acids with aromatic rings [3]. LAT, especially
its subtype LAT1, was reported to be highly expressed in
many cancer cell lines and positively correlates with tumor
growth [4, 5]. So far, 18F-AMT is the most suitable amino
acid transporter-targeting radiotracer for tumor imaging,
regardless of low synthesis yield and requirement of an on-
site cyclotron to produce 18F.
Although PET has emerged as an advanced imaging tool
for cancer diagnosis, only limited facilities around the world
can aﬀord complete armamentarium of PET and cyclotron
for the local production of short-lived positron-emitting
radionuclides such as 11Ca n d18F. Therefore, mature tech-
nologies, thatis, single photonemission computedtomogra-
phy(SPECT)oritscombinationwithcomputedtomography
(CT), still play important and irreplaceable roles in nuclear
imagingarea[6].ThemostcommonradionuclideforSPECT
is technetium-99m (99mTc, t1/2 = 6.02h), which is produced
byin-house generatorand doesnotrequirethecyclotron[7].
Due to their similar chemistry, the diagnostic radioisotope
99mTc and the therapeutic radioisotope rhenium-188 (188Re)
could be labeled to the same ligand, which leads to the
diagnostic/therapeutic matched pair. Unlike most of the
cyclotron-produced radionuclides that utilize the covalent
chemistry for labeling, 99mTc requires a “chelator” to conju-
gate the radionuclide with the target ligand. The nitrogen,2 Journal of Biomedicine and Biotechnology
oxygen, and sulfur combinations have been shown to be
stable chelators for 99mTc such as N4 (e.g., DOTA, cyclam-
14), N3S( e . g . ,M A G - 3 ) ,N 2S2 (e.g., ECD), NS3,S 4 (e.g.,
sulfur colloid), diethylenetriamine pentaacetic acid (DTPA),
O2S2 (e.g., DMSA), and hydrazinonicotinamide (HYNIC)
[8–13].
Here,wereportthesynthesisofprecursorO-[3-(1,4,8,11-
tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N4-
AMT) and its radiolabeling with 99mTc. In vitro cellular
uptake kinetics and planar scintigraphic imaging of 99mTc-
N4-AMT were also evaluated.
2.Materialsand Methods
All chemicals of analytical grade and solvents of HPLC grade
forcompoundsynthesiswere purchased fromSigma-Aldrich
(St. Louis, MO). 1H-, 13C-NMR spectra were performed
on Bruker 300MHz spectrometer in CDCl3,C D 3OD, and
D2O. Tetramethylsilane was used as an external standard.
Chemical shifts were reported in δ (ppm) and J values
in hertz. Sodium pertechnetate (Na99mTcO4)w a so b t a i n e d
from 99Mo/99mTc generator in Mallinckrodt (Houston, TX).
2.1. Synthesis of Precursor N4-AMT
2.1.1. α-Methyl Tyrosine Ethylester 2. The synthetic strate-
gies for precursor N4-AMT are demonstrated in Figure 1.
Thionyl chloride (10mL; 137.42mmol) was added to a
solution of α-methyltyrosine 1 (10.00g; 51.22mmol) in
anhydrous ethanol (60mL) at 0◦C, and then heated at 78◦C
for 4h while stirring. After cooling, the reaction mixture
was reduced to 20mL, and then 10mL of triethylamine
was added into it. The mixture was poured into 100mL
of water and extracted with chloroform. The combined
organic layers were dried over MgSO4 and evaporated. The
desired compound was obtained as white solid. Yield: 9.00g
(40.32mmol, 78.75%). 1H-NMR (CDCl3) δ = 7.02 (d, 2H, J
= 8.4Hz), 6.70 (d, 2H, J = 8.4Hz), 4.22 (dd, 2H, J = 7.2Hz,
J = 7.8Hz), 3.14 (dd, 2H, J = 13.5Hz, J = 13.5), 1.42 (s, 3H),
1.33 (t, 3H, J = 16.2Hz)ppm. 13C-NMR δ = 175.47, 156.36,
130.66,126.39,114.87,61.05,58.65,45.29, 24.08,13.07ppm,
MS: m/z = 224.23 [M]+.
2.1.2. N-t-Butoxycarbonyl-α-Methyl Tyrosine Ethylester 3.
Compound 2 (2.09g; 9.36mmol) was dissolved in 40mL
of anhydrous DMF under nitrogen and treated with tri-
ethylamine (2.78mL; 20mmol) while stirring. Ditertiarbutyl
dicarbonate (3.27g; 15mmol) was added to the reaction
mixture and stirred over night at room temperature. The
solvent was removed under reduced pressure to yield a
residue, which was extracted with ethyl acetate and dried
with anhydrous MgSO4. The extraction was ﬁltered and
evaporated to give yellow oil which was puriﬁed by column
chromatography on silica gel and eluted with hexane: ethyl
acetate (5:1.5v/v). After evaporation of the solvent, yellow
oil 3 was obtained. Yield: 2.00g (6.18mmol, 66.20%). 1H-
NMR (CDCl3) δ = 6.97 (d, 2H, J = 8.4Hz), 6.75 (d,
2H, J = 8.7Hz), 4.22 (dd, 2H, J = 2.7Hz, J = 7.2Hz),
3.32 (dd, 2H, J = 15.0Hz, J = 13.5), 1.55 (s, 3H), 1.48 (s,
9H), 1.32 (t, 3H, J = 18.0Hz)ppm. 13C-NMR δ = 174.16,
155.04, 154.51, 131.16, 128.50, 115.14, 77.25, 61.64, 60.54,
40.99, 28.39, 23.55, 14.77ppm, MS: m/z = 324.36 [M]+.
2.1.3.N-t-Butoxycarbonyl-O-[3-Hydroxypropyl]-α-Methyl Ty-
rosine Ethylester 4. Sodium metal (0.09g; 14.02mmol) was
dissolved in 30mL of anhydrous ethanol with stirring under
nitrogen. Compound 3 (1.00g; 3.09mmol) was dissolved in
50mL of anhydrous ethanol and treated with sodium ethox-
idesolutionandreﬂuxedfor2.5hat70◦C.3-Bromopropanol
(0.56mL; 6.18mmol) was added and continued heating over
night. The ethanol was removed under reduced pressure and
replaced with 40mL of ethyl acetate, washed with water,
and dried over MgSO4. After removal of the solvent, it
was puriﬁed by silica gel column chromatography (hexane:
ethylacetate 2:1), giving 0.83g (2.17mmol, 71% yield) of
the product as clear yellow oil. 1H-NMR (CDCl3) δ = 7.01
(d, 2H, J = 6.3Hz), 6.81 (d, 2H, J = 6.6Hz), 4.20 (dd, 2H, J
= 5.1Hz, J = 5.1Hz), 4.12 (t, 2H, J = 15.0Hz), 3.86 (t, 2H,
J = 10.2Hz), 3.16 (dd, J = 13.5Hz, J = 12.9Hz), 2.06 (m,
2H), 1.54 (s, 3H),1.47 (s, 9H), 1.31 (t,3H, J = 12.3Hz)ppm.
13C-NMR δ = 174.01, 171.91, 157.73, 154.35, 131.07, 128.65,
114.14, 79.39, 65.65, 61.54, 60.40, 60.24, 40.79, 32.01, 28.39,
23.58, 14.15ppm, MS: m/z = 381.033 [M]+.
2.1.4. N-t-Butoxycarbonyl-O-[3-Br-Propyl]-α-Methyl Tyro-
sine Ethylester 5. A solution of 4 (5.44g; 16.82mmol)
and 1,3-dibromopropane(136.74g;677.30mmol) in100mL
acetone was purged with nitrogen for 15min. Potassium
carbonate (22.62g; 163.69mmol) was added to the reaction
mixture,themixturewasthenreﬂuxedfor12hat75◦C.After
the removal of solvents and excessive reagents underreduced
pressure, the residue was dissolved in chloroform, washed
with water, and dried in anhydrous magnesium sulfate. A
yellow liquid was puriﬁed by silica gel ﬂash chromatography
(hexane: ethylacetate, 2:1) to furnish compound 5 as pale
yellow liquid. Yield: 4.80g (7.52mmol, 64.69%). 1H-NMR
(CDCl3) δ = 7.02 (d, 2H, J = 9.00Hz), 6.82 (d, 2H, J =
9.00Hz), 4.23 (dd, 2H, J = 27.00), 4.09 (t, 2H, J = 12.00Hz),
3.61 (t, 2H, J = 12.00Hz), 3.32, 3.16 (d, 2H, J = 15.00,
12.00Hz), 2.34 (dd, J = 24.00Hz), 1.54 (s, 3H), 1.47 (s, 9H),
1.32 (t, 3H, J = 15.0Hz)ppm. 13C-NMR δ = 173.96, 157.63,
154.32, 131.09, 128.78, 114.18, 77.48, 65.24, 61.51, 60.35,
40.80,30.00,28.40,23.60,14.19ppm.MS:m/z = 446.3[M]+.
2.1.5. N1,N 4-Dioxylyl-1,4,8,11-Tetraazabicyclotetradecane
(N1,N4-Cyclooxamide) 6. 1,4,8,11-tetraazacyclotetradecane
(cyclam) (15.00g; 74.88mmol) was dissolved in 150mL of
anhydrousethanol,anddiethyloxalate(10.94g;74.88mmol)
was added. The reaction mixture was reﬂuxed 18h
at 75◦C. The solvent was rotary evaporated, and the
crude product was recrystallized in acetone: ethanol to
yield white crystals of N1,N4-dioxylyl-1,4,8,11-1,5,8,12-
tetraazabicyclotetradecane (N1,N4-cyclooxamide) 6.Y i e l d :
13.64g (17.31mmol, 72.00%). 1H-NMR (CDCl3) δ =
4.35 (m, 2H), 375 (m, 2H), 3.40 (m, 2H), 2.77 (m, 2H),
2.68 (m, 2H), 2.54 (m, 2H), 2.43 (m, 4H), 1.75 (m, 2H),Journal of Biomedicine and Biotechnology 3
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Figure 1: Synthetic scheme of precursor N4-AMT.
1.24 (m, 2H)) ppm. 13C-NMR δ = 158.55, 49.92, 49.38,
47.73, 44.13, 25.42ppm. MS: m/z = 255.33 [M]+.
2.1.6. N-t-Butoxycarbonyl-O-[3-(N1,N4-Dioxylyl-1,4,8,11-
Tetraazabicyclotetradecane)-Propyl]-α-Methyl Tyrosine Ethyl-
ester 7. Compound 6 (1.00g; 3.93mmol) was dissolved in
20mL of anhydrous DMF and treated with a solution of N-
t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine eth-
ylester 5 (1.74g; 3.93mmol) in 40mL of DMF under
nitrogen atmosphere. The reaction mixture was heated to
reﬂux for 18h at 75◦C and then allowed to cool down to
room temperature. The solvent was removed in vacuo.T h e
residue was dissolved in chloroform (30mL), washed with
water and 1M Na2CO3, (12mL), and then separated for
the organic layer. It was dried with anhydrous Magnesium
sulfate, ﬁltered, and evaporated. The crude compound was
puriﬁed by silica gel column chromatograph (chloroform:
methanol 9:1). Yield: 1.00g (1.63mmol, 42.00%). 1H-NMR
(CDCl3) δ = 7.00 (d, 2H, J = 9.00Hz), 6.79 (d, 2H, J =
9.00Hz), 4.56 (m, 2H), 4.22 (t, 2H, J = 12.0Hz), 3.95 (m,
2H), 3.67 (m, 2H), 3.55 (t, 2H, J = 15.0Hz), 3.30 (m, 4H),
2.81 (m, 12H), 1.88 (m, 6H), 1.54 (s, 3H), 1.47 (s, 9H),
1.32 (t, 3H, J= 15.0Hz) ppm. 13C-NMR δ = 173.97, 158.65,
158.06, 157.91, 154.31, 131.01, 128.34, 114.04, 79.38, 77.27,
66.01, 61.50, 60.26, 53.76, 52.76, 49.20, 48.41, 47.54, 46.15,
45.83, 44.50, 42.60, 40.84, 28.40, 26.39, 23.57, 23.36, 23.07,
14.14ppm. MS: m/z = 618.38 [M]+.
2.1.7. O-[3-(N1,N4-Dioxylyl-1,4,8,11-Tetraazabicyclotetrade-
cane)-Propyl]-α-Methyltyrosine Ethylester 8. Compound 7
(0.25g; 0.40mmol) was dissolved in dichloromethane
(10mL), and triﬂuoroacetic acid (1.0mL) was added to it.
The solution was stirred over night at room temperature,
and volatiles were removed in vacuo. The crude compound
was puriﬁed by chromatography over silica gel (chloroform:
methanol 9:1) as white solid. Yield: 0.20g (0.39mmol;
95.69%). 1H-NMR (CD3OD) δ = 7.14 (d, 2H, J = 9.0Hz),
6.94 (d, 2H), 4.33 (m, 4H), 4.05 (t, 2H, J = 9.0Hz),
3.85 (m, 2H), 3.71 (m, 2 H), 3.26 (m, 13H), 2.07 (m,
6H), 1.58 (s, 3H), 1.33 (t, 3H, J = 15.0Hz) ppm. 13C-
NMR δ = 170.65, 161.87, 161.42, 159.70, 159.02, 158.67,
131.01, 125.14, 118.79, 114.65, 65.34, 62.47, 60.33, 56.92,
52.16, 51.26, 45.64, 45.31, 44.50, 43.20, 42.05, 24.31, 22.00,
21.39, 21.03, 16.96, 12.90ppm, MS: m/z = 517.63 [M]+.
2.1.8. O-[3-(1,4,8,11-Tetraazabicyclohexadecane)-Propyl]-α-
Methyl Tyrosine (N4-AMT) 9. To a solution of compound 8
(0.20g; 0.39mmol) in a 5mL of water, 10N NaOH (2mL)
was added, stirred, and reﬂuxed over night at 90◦C. The
solvent was evaporated under vacuum, giving white solid,
which was dissolved in 5mL of water and neutralized
with 5N HCl solution to pH = 7. It was lyophilized and
obtained as white solid. The solid was stirred in 25mL
anhydrous methanol, ﬁltered, and evaporated to aﬀord an
oﬀ white solid. Yield: 0.20g (0.46mmol: 99.0%). 1H-NMR
(D2O) δ = 7.21 (d, 2H, J = 9.00Hz), 7.00 (d, 2H, J =
9.00Hz), 4.14 (t, 2H, J = 12.0Hz), 3.10 (m, 5H), 2.94 (m,
2H), 2.84 (m, 13H), 1.95 (m, 6H), 1.33 (s, 3H) ppm.13C-
NMR δ = 180.69, 163.42, 163.16, 162.88, 162.60, 157.06,
131.40, 129.19, 117.57, 115.26, 115.10, 112.93, 66.25, 60.73,
53.69, 51.46, 49.88, 49.26, 48.04, 47.84, 46.60, 45.42, 45.07,
43.94, 24.71, 24.32, 23.62, 22.55 ppm. MS: m/z = 436.327
[M]+.
2.2. Radiosynthesis of 99mTc-N4-AMT. Radiolabeling of N4-
AMT with 99mTc was performed in a standard manner [14].
Brieﬂy, radiosynthesis of 99mTc-N4-AMT was achieved by
adding a required amount of sodium pertechnetate into
a vial containing precursor N4-AMT and SnCl2 (100μg).
Radiochemical purity was assessed by high-performance
liquid chromatography (HPLC), equipped with NaI and UV
detector (274nm), and was performed using a C-18 reverse
column with a mobile phase of acetonitrile:water (7:3) at a
ﬂow rate of 0.5mL/min.4 Journal of Biomedicine and Biotechnology
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Figure 3: In vitro cellular uptake of 99mTc-N4-AMT. The cellular
uptake kinetics of 99mTc-N4-AMT and 99mTc-N4 was conducted in
the rat breast tumor cell line 13762. Data were expressed in mean ±
S.D. percent of cellular uptake (%Uptake).
2.3. In Vitro Cellular Uptake of 99mTc-N4-AMT. Rat mam-
mary tumor cell line 13762 was obtained from American
Type Culture Collection (Rockville, MD). The same cell line
was used to create the animal model for in vivo evaluation.
Cells were maintained at 37◦C in a humidiﬁed atmosphere
containing 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium
and nutrient mixture F-12 Ham (DMEM/F12; GIBCO,
Grand Island, NY). Cells were plated to 6-well tissue culture
plates (2 × 105 cells/well) for two days before the study, and
incubated with 99mTc-N4-AMT (0.05mg/well, 8uCi/well)
or 99mTc-N4 chelator itself (0.025mg/well, 8uCi/well) for
15min–4h.A ft erincubation,c ellswere washed withice-cold
PBS twice and detached by adding 0.5mL of trypsin. Cells
were then collected and the radioactivity was measured with
gamma counter (Cobra Quantum; Packard, MN). Data was
expressed in mean ± S.D. percent of cellular uptake.
2.4. In Vivo Tissue Distribution Studies. All animal work was
c a r r i e do u ti nt h eS m a l lA n i m a lI m a g i n gF a c i l i t y( S A I F )
at University of Texas MD Anderson Cancer Center under
the protocol approved by Institutional Animal Care and Use
Committee (IACUC). Tissue distribution studies of 99mTc-
N4-AMT (study I, n = 9) or 99mTc-N4 (study II, n = 9) were
conducted by using normal female Fischer 344 rats (150 ±
25 g,n = 18)(Harlan Sprague-Dawley,Indianapolis, IN).For
each radiotracer, nine rats were divided into three groups
for three time intervals (0.5, 2, 4h). The injection activity
was 25 ± 0.5μCi/rat intravenously. At each time interval,
the rats were sacriﬁced, and the selected tissues were excised,
weighed, and measured for radioactivity by gamma counter.
Data from each sample were represented as the percentage
of the injected dose per gram of tissue wet weight (%ID/g).
Counts from a diluted sample of the original injection were
used as the reference.
2.5. Planar Scintigraphic Imaging Studies of 99mTc-N4-AMT.
Female Fischer 344 rats were inoculated subcutaneously
with 0.1mL of 13762 rat mammary tumor cell suspension
(105 cells/rat) into the right posterior legs using 22-gauge
needles. Imaging studies were performed 14 to 17 days after
inoculation when tumors reached approximately 1cm in
diameter. The anesthetized rats were injected intravenously
with 99mTc-N4-AMT (0.3mg/rat, 300μCi/rat; n = 3) or
with 99mTc-N4 (0.15mg/rat, 300μCi/rat; n = 3), respectively.
Planar scintigraphic images were obtained using M-CAM
(Siemens Medical Solutions, Hoﬀman Estates, IL) equipped
with a Low-Energy High-Resolution collimator at 30–
120min. The ﬁeld of view was 53.3cm × 38.7cm. The
intrinsic spatial resolution was 3.2mm and the pixel size was
from 19.18mm (32 × 32, zoom = 1) to 0.187mm (1024 ×
1024, zoom = 3.2). Computer outlined regions of interest
(ROI) (counts per pixel) of tumors, and normal muscle
tissues at symmetric sites were used to calculate tumor-to-
muscle (T/M) ratios.
3.Resultsand Discussion
3.1. Chemistry. N4-AMT was synthesized via an eight-
step procedure (Figure 1). Commercially available α-
methyl tyrosine 1 was converted into corresponding acid
chloride, then to ethyl ester by reacting with thionyl
chloride in ethanol. The amine in α-methyl tyrosine
ethyl ester 2 w a sp r o t e c t e da si t sB o c - d e r i v a t i v eN -
t-butoxycarbonyl-α-methyl tyrosine ethylester 3 with
triethylamine and di-t-butyldicarbonate in DMF. The
chain at the –OH group was extended when compoundJournal of Biomedicine and Biotechnology 5
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Figure 4: Planar scintigraphicimaging studies of 99mTc-N4-AMT. Scintigraphic images of Fisher 344 tumor bearing rats were acquired, and
computer outlined regions of interest (counts per pixel) in the tumors (T) and the symmetrical muscle tissues (M) were used to determine
T/M count density ratios.
3 was treated with 1, 3-dibromopropane and obtained as
N-t-butoxycarbonyl-O-[3-bromopropyl]-α-methyl tyrosine
ethylester 4. Acylation of 1,4,8,11-tetraazacyclo-tetradecane
(cyclam) with diethyloxalate led to N1,N4-dioxalyl 1,4,8,11-
tetraazacyclotetradecane (N1,N4-cyclamoxamide) 5.U n d e r
SN2 condition 4 and 5 were eﬃciently converted to alkylated
compound N-t-butoxycarbonyl-O-[3-(N1,N4-dioxalyl-1,4,
8,11-tetraazacyclotetradecane)-propyl]-α-methyl tyrosine
ethylester 6.E x p o s u r eo f6 to triﬂuoroacetic acid in
CH2Cl2 caused qualitative de-t-butoxycarboxylation to yield
O-[3-(N1,N 4-dioxalyl 1,4,8,11-tetraazacyclotetradecane)-
propyl]-α-methyl tyrosine ethylester 7.1 0NN a O Hi nw a t e r
at 75◦C promoted the hydrolysis of ester to acid and a
simultaneous deoxalation of 7 to yield the ﬁnal compound
O-[3-(1,4,8,11-tetraazacyclotetradecan)-propyl]-α-methyl
tyrosine (N4-AMT) 8. The total synthesis yield was 14%,
which can be adapted to industrial manufacturing. The
structure and purity of the compounds at each step were
validated by 1H- and 13C-NMR, mass spectra, and HPLC.
3.2. Radiosynthesis. As shown in Figure 2,p r e c u r s o rN 4 -
AMT could be labeled with 99mTc successfully in a high
radiochemical purity (>96%). The retention time of 99mTc-
N4-AMT was 6.899min. Given that 99mTc-N4-AMT is a
kit-product and labeled without any further puriﬁcation,
the radiochemical yield was assumed to be identical to its
radiochemical purity. In this study, we labeled amino acid
α-methyltyrosine AMT with 99mTc using cyclam N4 as the
chelator because of its stable chelating ability and fast renal
clearance. 99mTc was selected as the radionuclide due to its
favorable physical characteristics, suitable half-life, and cost-
eﬀectiveness.
3.3. In Vitro Cellular Uptake of 99mTc-N4-AMT. The cellular
uptake kinetics of 99mTc-N4-AMT and 99mTc-N4 in rat
breast tumor cell line 13762 is shown in Figure 3.T h e r e
was a drastically increased uptake for 99mTc-N4-AMT in the
tumor cells at 15–240min, but not for 99mTc-N4 chelator.
These ﬁndings suggest that by adding the amino acid AMT,
99mTc-N4-AMT can enter and accumulate into tumor cells
eﬀectively and rapidly. To further investigate the transport
mechanisms of 99mTc-N4-AMT, the competitive inhibition
study using various types of transporter inhibitors will be
conducted in the future.
3.4. In Vivo Evaluation of 99mTc-N4-AMT. The result of the
in vivo biodistribution studies in the normal Fischer rats at
0.5,2,and4hoursafterintravenousadministration of 99mTc-
N4-AMT is shown in Table 1. Planar scintigraphic images
of 99mTc-N4-AMT and 99mTc-N4 at 30, 60, and 120min in
breast tumor-bearing rats are shown in Figure 4.T / Mr a t i o s
of 99mTc-N4-AMT were 2.3–4.0, whereas those of 99mTc-N4
were 1.9–2.5, respectively. Tumors could be clearly visualized
by 99mTc-N4-AMT, but not by 99mTc-N4. In addition, the
rat kidneys showed intense activity of 99mTc-N4-AMT in
the planar images, which was consistent with the results
from the in vivo biodistribution studies in the normal rats.
This may be due to the nature of AMT, an inhibitor of
tyrosine hydroxylase that cannot be excreted from kidneys
and hence crystallized in the proximal tubules because of
its poor solubility at the hydrogen ion concentrations of
body ﬂuids (pH 5–8) [15]. In the future, in vivo uptake
blocking study using the unlabeled AMT will be performed
to ascertain whether accumulation of 99mTc-N4-AMT in the
kidney is attributed to AMT module.
4.Conclusion
In conclusion, eﬃcient synthesis of N4-AMT was achieved.
In vitro cellular uptake and in vivo imaging ﬁndings collec-
tively suggest that 99mTc-N4-AMT is a potential radiotracer
for breast cancer imaging. In compliance with the chelating6 Journal of Biomedicine and Biotechnology
Table 1: Biodistribution of 99mTc-N4-AMT in Normal Fischer 344 Rats.
30MIN 120MIN 240MIN
blood 0.74 ± 0.024 0.28 ± 0.010 0.18 ± 0.008
heart 0.18 ± 0.013 0.08 ± 0.006 0.05 ± 0.003
lung 0.44 ± 0.029 0.22 ± 0.004 0.13 ± 0.008
thyroid 0.57 ± 0.040 0.31 ± 0.015 0.24 ± 0.012
pancreas 0.18 ± 0.006 0.09 ± 0.005 0.06 ± 0.002
liver 1.40 ± 0.077 0.83 ± 0.045 0.60 ± 0.023
spleen 0.24 ± 0.004 0.19 ± 0.002 0.18 ± 0.011
kidney 5.77 ± 0.355 5.32 ± 0.180 4.74 ± 0.332
stomach 0.50 ± 0.029 0.42 ± 0.031 0.43 ± 0.026
intestine 0.33 ± 0.019 0.18 ± 0.010 0.13 ± 0.006
uterus 0.34 ± 0.014 0.14 ± 0.023 0.08 ± 0.004
muscle 0.09 ± 0.007 0.03 ± 0.002 0.02 ± 0.001
bone & joint 0.27 ± 0.061 0.11 ± 0.006 0.06 ± 0.003
brain 0.03 ± 0.005 0.01 ± 0.001 0.01 ± 0.000
Each value is the percentage of injected dose per gram weight (n = 3)/time interval. Each datum represents the mean of three measurements with standard
deviation.
capability of N4, N4-AMT could be labeled with positron
emitting radionuclides such asG a l l i u m - 6 8o rw i t hs h o r t -
ranged beta emitters for internal radiotherapeutic purposes
hereafter.
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